Cargando…
Calcified Middle Cranial Fossa Mass
A 21-year-old male presented for evaluation of transient loss of consciousness and was found to have a hyperdense mass in the left middle fossa. He underwent craniotomy for tumor resection. Intra- and extradural invasion was noted. Gross total resection was achieved. Pathology demonstrated a densely...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332251/ https://www.ncbi.nlm.nih.gov/pubmed/28255529 http://dx.doi.org/10.1055/s-0037-1598112 |
_version_ | 1782511509604139008 |
---|---|
author | Botros, James Hatanpaa, Kimmo Isaacson, Brandon Barnett, Samuel L. |
author_facet | Botros, James Hatanpaa, Kimmo Isaacson, Brandon Barnett, Samuel L. |
author_sort | Botros, James |
collection | PubMed |
description | A 21-year-old male presented for evaluation of transient loss of consciousness and was found to have a hyperdense mass in the left middle fossa. He underwent craniotomy for tumor resection. Intra- and extradural invasion was noted. Gross total resection was achieved. Pathology demonstrated a densely cellular neoplasm with predominately spindle cell morphology in a collagen-containing stroma, areas of vascular proliferation, focal mineralization, and regions of cartilage formation. High mitotic index and regions of necrosis were seen. Based on the final diagnosis of osteosarcoma, the patient was referred for chemotherapy and radiation. Intracranial osteosarcoma is a nonmeningiomatous mesenchymal tumor. Most osteosarcomas are meningeal-based and supratentorial. Presentation depends on tumor location and may include focal neurologic deficits, cranial neuropathy, seizures, or symptoms of increased intracranial pressure. Given the relative rarity of intracranial osteosarcoma, there are no established guidelines for treatment, and therapy is guided by experience with systemic osteosarcoma. Gross total resection is recommended whenever feasible. Both chemotherapy and radiation therapy are used as adjuvant therapy. Regardless of treatment, osteosarcoma remains a highly aggressive malignancy with a poor prognosis. Morbidity and mortality may be the result of local recurrence or development of pulmonary or skeletal metastasis. |
format | Online Article Text |
id | pubmed-5332251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-53322512017-03-02 Calcified Middle Cranial Fossa Mass Botros, James Hatanpaa, Kimmo Isaacson, Brandon Barnett, Samuel L. J Neurol Surg Rep A 21-year-old male presented for evaluation of transient loss of consciousness and was found to have a hyperdense mass in the left middle fossa. He underwent craniotomy for tumor resection. Intra- and extradural invasion was noted. Gross total resection was achieved. Pathology demonstrated a densely cellular neoplasm with predominately spindle cell morphology in a collagen-containing stroma, areas of vascular proliferation, focal mineralization, and regions of cartilage formation. High mitotic index and regions of necrosis were seen. Based on the final diagnosis of osteosarcoma, the patient was referred for chemotherapy and radiation. Intracranial osteosarcoma is a nonmeningiomatous mesenchymal tumor. Most osteosarcomas are meningeal-based and supratentorial. Presentation depends on tumor location and may include focal neurologic deficits, cranial neuropathy, seizures, or symptoms of increased intracranial pressure. Given the relative rarity of intracranial osteosarcoma, there are no established guidelines for treatment, and therapy is guided by experience with systemic osteosarcoma. Gross total resection is recommended whenever feasible. Both chemotherapy and radiation therapy are used as adjuvant therapy. Regardless of treatment, osteosarcoma remains a highly aggressive malignancy with a poor prognosis. Morbidity and mortality may be the result of local recurrence or development of pulmonary or skeletal metastasis. Georg Thieme Verlag KG 2017-01 /pmc/articles/PMC5332251/ /pubmed/28255529 http://dx.doi.org/10.1055/s-0037-1598112 Text en © Thieme Medical Publishers |
spellingShingle | Botros, James Hatanpaa, Kimmo Isaacson, Brandon Barnett, Samuel L. Calcified Middle Cranial Fossa Mass |
title | Calcified Middle Cranial Fossa Mass |
title_full | Calcified Middle Cranial Fossa Mass |
title_fullStr | Calcified Middle Cranial Fossa Mass |
title_full_unstemmed | Calcified Middle Cranial Fossa Mass |
title_short | Calcified Middle Cranial Fossa Mass |
title_sort | calcified middle cranial fossa mass |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332251/ https://www.ncbi.nlm.nih.gov/pubmed/28255529 http://dx.doi.org/10.1055/s-0037-1598112 |
work_keys_str_mv | AT botrosjames calcifiedmiddlecranialfossamass AT hatanpaakimmo calcifiedmiddlecranialfossamass AT isaacsonbrandon calcifiedmiddlecranialfossamass AT barnettsamuell calcifiedmiddlecranialfossamass |